It may not be suitable for: Individuals with untreated hormone-sensitive cancers
Dekant R, Langer M, Lupp M, Adaku Chilaka C, Mally A (2021) In vitro and in vivo analysis of ochratoxin A derived glucuronides and mercapturic acids as biomarkers of exposure
Trial results vary by drug, dose, baseline weight, adherence, side-effect tolerance, and whether patients can stay on treatment
If you are ever uncertain, contact your provider before taking your injection
As federal rules set a new baseline, additional states may layer on further requirements, ensuring GLP-1 PAs are processed electronically by default nationwide